Sugi Predict

Sugi Predict / Compounds / SCHEMBL980791

SCHEMBL980791

SCHEMBL980791

COC(C)(C)CCC(=O)/C(C)=C/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1ccc(C)c(C)c1C

nearest known ligand 0.35

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ PTGS1 P23219 2/20 0.35
▸ ESR1 P03372 1/20 0.35
▸ PGR P06401 1/20 0.35
▸ ADORA3 P0DMS8 1/20 0.35
▸ CHRM1 P11229 1/20 0.35
▸ SLC6A2 P23975 1/20 0.35
▸ SLC6A4 P31645 1/20 0.35
▸ OPRM1 P35372 1/20 0.35
▸ KCNH2 Q12809 1/20 0.35
▸ ABCC4 O15439 1/20 0.34
▸ NR1I2 O75469 1/20 0.34
▸ ABCB11 O95342 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2835848 0.82 PTGS1 (0.46) PTGS1PGRNR1I2ALDH1A1MAPT
SCHEMBL2834930 0.78 PTGS1 (0.41) PTGS1PGRNR1I2ALDH1A1MAPT
SCHEMBL2841251 0.78 PTGS1 (0.41) PTGS1PGRNR1I2ALDH1A1MAPT
SCHEMBL31571698 0.77 ALDH1A1 (0.38) PTGS1ESR1PGRADORA3CHRM1
SCHEMBL2831023 0.76 PTGS1 (0.40) PTGS1PGRNR1I2ALDH1A1MAPT
SCHEMBL2832499 0.73 ALDH1A1 (0.62) PTGS1PGRADORA3CHRM1SLC6A2
SCHEMBL2838889 0.72 PTGS1 (0.36) PTGS1PGRNR1I2ALDH1A1MAPT
SCHEMBL30555741 0.72 NR1I2 (0.58) PTGS1PGRNR1I2ALDH1A1MAPT
SCHEMBL29651369 0.71 MAPT (0.41) PTGS1ESR1PGRADORA3CHRM1
SCHEMBL5200105 0.70 NR1I2 (0.56) PTGS1PGRNR1I2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013144595-A1 PERIDININ-CHLOROPHYLL BINDING PROTEINS PROTEIN TECHNOLOGIES LIMITED (GB) 2013-10-03 — — WO claimed
US-20260144834-A1 ANTIMICROBIAL FEED ADDITIVE Axitan Ltd. (GB) 2026-05-28 — — US disclosed
US-20260123660-A1 Particles Containing a Lipid Matrix Core and Active Ingredient LONZA SALES AG (CH) 2026-05-07 — — US disclosed
EP-4054348-B1 PARTICLES CONTAINING A LIPID MATRIX CORE AND ACTIVE INGREDIENT LONZA SALES AG (CH) 2026-01-28 — — EP disclosed
US-12471609-B2 Reducing the risk of viral infection due to viral contaminated feed NOVUS INTERNATIONAL, INC. (US) 2025-11-18 — — US disclosed
US-12465075-B2 Particles containing a lipid matrix core and active ingredient LONZA SALES AG (CH) 2025-11-11 — — US disclosed
EP-4642253-A1 USE OF MICROALGAE AND MICROALGAE DERIVED COMPONENTS IN CULTIVATED FOOD PRODUCTION Weforesea Ltd. (IL) 2025-11-05 — — EP disclosed
US-20250281440-A1 METHOD TO IMPROVE GROWTH PERFORMANCE, LIVABILITY, CARCASS CHARACTERISTICS AND/OR MILK QUALITY IN SWINE NUTRIQUEST, LLC 2025-09-11 — — US disclosed
US-12349704-B2 High quality cultured meat, compositions and methods for producing same ALEPH FARMS LTD. (IL) 2025-07-08 — — US disclosed
US-12310386-B2 Reducing the risk of viral infection due to viral contaminated feed NOVUS INTERNATIONAL, INC. (US) 2025-05-27 — — US disclosed
US-20050059635-A1 Carotenoid ester analogs or derivatives for controlling C-reactive protein levels CARDAX PHARMACEUTICALS, INC. 2005-03-17 — — US disclosed
US-20050059659-A1 Carotenoid analogs or derivatives for controlling C-reactive protein levels CARDAX PHARMACEUTICALS, INC. 2005-03-17 — — US disclosed
US-20050049248-A1 Carotenoid ether analogs or derivatives for controlling C-reactive protein levels CARDAX PHARMACEUTICALS, INC. 2005-03-03 — — US disclosed
US-20050037995-A1 Carotenoid ester analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury CARDAX PHARMA, INC. 2005-02-17 — — US disclosed
US-20050026874-A1 Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease CARDAX PHARMACEUTICALS, INC. 2005-02-03 — — US disclosed
US-20050009930-A1 Carotenoid analogs or derivatives for controlling connexin 43 expression CARDAX PHARMA, INC. 2005-01-13 — — US disclosed
US-20050009788-A1 Carotenoid ester analogs or derivatives for controlling connexin 43 expression CARDAX PHARMACEUTICALS, INC. 2005-01-13 — — US disclosed
US-20050009758-A1 Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease CARDAX PHARMA, INC. 2005-01-13 — — US disclosed
US-20050004235-A1 Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease CARDAX PHARMACEUTICALS, INC. 2005-01-06 — — US disclosed
US-20040175407-A1 Microorganism coating components, coatings, and coated surfaces REACTIVE SURFACES, LTD. 2004-09-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050037995-A1 Carotenoid ester analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury CPT1A, TXNRD2, PC PTGS1 97/4885ESR1 2730/4885PGR 3696/4885
US-20260144834-A1 ANTIMICROBIAL FEED ADDITIVE ELOVL6, CROCC, ELOC PTGS1 4708/4885ESR1 3577/4885PGR 4682/4885
US-20250281440-A1 METHOD TO IMPROVE GROWTH PERFORMANCE, LIVABILITY, CARCASS CHARACTERISTICS AND/OR MILK QUALITY IN SWINE PIGS, GLO1, IGFBP6 PTGS1 1260/4885ESR1 4545/4885PGR 2217/4885
US-20050009788-A1 Carotenoid ester analogs or derivatives for controlling connexin 43 expression GJA1, GJB2, CRY1 PTGS1 429/4885ESR1 935/4885PGR 2684/4885
US-20050009930-A1 Carotenoid analogs or derivatives for controlling connexin 43 expression GJA1, GJB2, CRY1 PTGS1 465/4885ESR1 1591/4885PGR 2818/4885
US-20050059635-A1 Carotenoid ester analogs or derivatives for controlling C-reactive protein levels TTPA, PROC, RBP4 PTGS1 187/4885ESR1 2998/4885PGR 2454/4885
US-20050059659-A1 Carotenoid analogs or derivatives for controlling C-reactive protein levels RBP1, PROC, RBP4 PTGS1 157/4885ESR1 3778/4885PGR 2689/4885
US-20050026874-A1 Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease GYS2, HCCS, CPT1A PTGS1 773/4885ESR1 1859/4885PGR 2761/4885
US-20260123660-A1 Particles Containing a Lipid Matrix Core and Active Ingredient AUP1, MGLL, MBOAT4 PTGS1 2932/4885ESR1 4274/4885PGR 859/4885
US-20050049248-A1 Carotenoid ether analogs or derivatives for controlling C-reactive protein levels PROC, TTPA, CYC1 PTGS1 385/4885ESR1 1339/4885PGR 1989/4885
US-20050009758-A1 Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease NFE2L2, GPX4, CYP11B2 PTGS1 81/4885ESR1 1099/4885PGR 2215/4885
US-20050004235-A1 Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease GYS2, HCCS, CPT1A PTGS1 643/4885ESR1 4200/4885PGR 3550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.